Watchlist Price Alert

Apimeds Pharmaceuticals U... (APUS)

NYSE: APUS · Real-Time Price · USD

1.72

0.09 (5.52%)

At close: Jun 23, 2025, 1:04 PM

Apimeds Pharmaceuticals US Inc Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-275.61K	-300K	-427.76K	-271.73K	-559.07K	-104.16K	-27.83K	-56.38K	-66.19K
Interest Income	30.00	116.00	517.00	2.16K	5.58K	2.23K	n/a	n/a	n/a
Pretax Income	-311.63K	-332.52K	-449.36K	-296.47K	-566.97K	-110.02K	-36.08K	-64.63K	-74.59K
Net Income	-311.63K	-332.52K	-449.36K	-296.47K	-566.97K	-110.02K	-36.08K	-64.63K	-74.59K
Selling & General & Admin	275.61K	300K	427.76K	271.73K	530.52K	107.16K	5.38K	5.83K	4.07K
Research & Development	n/a	n/a	n/a	n/a	28.55K	-3K	22.44K	50.55K	62.12K
Other Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	275.61K	300K	427.76K	271.73K	559.07K	104.16K	27.83K	56.38K	66.19K
Interest Expense	36.05K	32.64K	22.12K	26.91K	13.48K	8.09K	8.25K	8.25K	8.41K
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	275.61K	300K	427.76K	271.73K	559.07K	104.16K	27.83K	56.38K	66.19K
Income Tax Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M
Shares Outstanding (Diluted)	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M
EPS (Basic)	-0.03	-0.03	-0.04	-0.03	-0.05	-0.01	-0.00	-0.01	-0.01
EPS (Diluted)	-0.02	-0.03	-0.04	-0.02	-0.04	-0.01	-0.00	-0.01	-0.01
EBITDA	-275.58K	-299.88K	-427.24K	-269.56K	-553.49K	-101.93K	-27.83K	-56.38K	-66.19K
EBIT	-275.58K	-299.88K	-427.24K	-269.56K	-553.49K	-101.93K	-27.83K	-56.38K	-66.19K
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a